TD114-2 (compound 29) is a potent, selective GSK-3β inhibitor (IC50 = 48 nM) with selectivity conferred by a key interaction with ARG141. It is a valuable research tool for studying GSK-3β's role in diabetes and neurodegenerative disease models, applicable in both in vitro and in vivo experimental settings.